0.29
+0.70%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Nicox
Its shares trade on Euronext Paris under the ticker ALCOX.PA. It has been listed since 2 November 1999. In the fiscal year to 31 December 2025, it reported revenue of €16.8m and a net loss of €2.4m. At that date it held total assets of €10.4m and shareholders' equity of €6.0m.
Nicox SA is an ophthalmology company. The company is headquartered in Valbonne, Paca. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 Nov 1999
- Employees
- 35
- Website
- nicox.com ↗
Leadership
Pay as last reported
- Mr. Damian MarronIndependent Chairman of the Board, since 2002€20,779
- Dr. Gavin SpencerChief Executive Officer, Director, since 2005
- Mr. Marc Le BozecIndependent Director€11,544
- Ms. Christine PlacetIndependent Director€8,128
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Nicox SA is known for its strong emphasis on innovative research and development activities. The company constantly strives to develop new and advanced solutions in the field of ophthalmology, which gives them a competitive advantage.
- Nicox SA possesses a robust intellectual property portfolio, including patents and licenses for various ophthalmic products and technologies. This not only protects their innovations but also provides potential licensing and collaboration opportunities.
Weaknesses
- Nicox SA heavily relies on key partnerships to conduct clinical trials, develop products, and commercialize their offerings. This dependency on external collaborations poses a risk, as any issues or disagreements with partners could negatively impact the company's operations.
- Despite their technological advancements, Nicox SA has a relatively limited market presence compared to some of its competitors. This restricted market reach may restrict their growth potential and market share.
Opportunities
- The global ophthalmic market is experiencing significant growth due to factors such as an aging population, rising prevalence of eye disorders, and increasing healthcare expenditure. Nicox SA can capitalize on this opportunity by introducing their innovative products to a larger customer base.
- Nicox SA has the potential to enhance its market position by establishing strategic collaborations and partnerships with renowned pharmaceutical or ophthalmic companies. Such partnerships can bring together complementary expertise, resources, and networks to drive mutual growth.
Threats
- The ophthalmic industry is highly competitive, with several established players and emerging companies vying for market dominance. Nicox SA faces the threat of competition, which may result in price wars, loss of market share, and reduced profitability.
- As an innovative pharmaceutical company, Nicox SA must navigate complex regulatory landscapes governing drug development, clinical trials, and product approvals. Changes in regulations or delays in obtaining necessary approvals can pose significant challenges and hinder their growth prospects.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.